DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
NEW YORK, March 05, 2018 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that members of the company’s management team will present at two upcoming investor conferences:
- Cowen & Company 38th Annual Health Care Conference
Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid, will present a corporate overview on Monday, March 12, 2018 at 2:10 p.m. ET. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, MA.
- BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
Yaron Werber, M.D., chief business and financial officer of Ovid, will present a corporate overview on Friday, March 23, 2018 at 10:00 a.m. ET. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York, NY.
Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. Archived replays of the webcasts will be available on the company's website for two weeks following each live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
[email protected]
